
Agilent Technologies A
$ 114.46
2.84%
Quarterly report 2025-Q4
added 03-03-2026
Agilent Technologies DSO Ratio 2011-2026 | A
Annual DSO Ratio Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 63.8 | 71 | 65.7 | 57.6 | 59.1 | 54.8 | 54.8 | 51.4 | 48.4 | 49.1 | 47.5 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71 | 47.5 | 56.7 |
Quarterly DSO Ratio Agilent Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.3 | - | 71.1 | 72 | - | - | - | 69.2 | 71.1 | - | - | 66 | 66.6 | - | 66 | 64 | 67.4 | 24.6 | 69.6 | 63.4 | 62.6 | 22.4 | 66.6 | 62 | 58.4 | 20.2 | 60.7 | 55 | 58.9 | 20.1 | 59.3 | 55.5 | 55.4 | 18.6 | 55.1 | 55.8 | 54.3 | 18.4 | 54.5 | 68.9 | 66.8 | 19 | 56.6 | 69.3 | 48.1 | 16.2 | 49.7 | 45.1 | 48.5 | 16.5 | 48.9 | 46.8 | 51.5 | 16.1 | 46.4 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 76.3 | 16.1 | 51.6 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
CareDx, Inc
CDNA
|
51.5 | $ 20.75 | -0.24 % | $ 1.11 B | ||
|
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
94.7 | $ 1.57 | 2.61 % | $ 2.09 M | ||
|
ICON Public Limited Company
ICLR
|
68.5 | $ 115.97 | -0.17 % | $ 9.57 B | ||
|
Illumina
ILMN
|
61.3 | $ 126.01 | 4.68 % | $ 20 B | ||
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M | ||
|
Lantheus Holdings
LNTH
|
80.5 | $ 83.18 | 2.48 % | $ 5.61 B | ||
|
Medpace Holdings
MEDP
|
50.4 | $ 418.03 | 1.07 % | $ 12.1 B | ||
|
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | ||
|
NeoGenomics
NEO
|
77.7 | $ 9.07 | 1.23 % | $ 1.16 B | ||
|
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | ||
|
National Research Corporation
NRC
|
29.4 | $ 16.88 | 2.06 % | $ 378 M | ||
|
Fulgent Genetics
FLGT
|
77.4 | $ 15.24 | 2.97 % | $ 461 M | ||
|
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M | ||
|
Senseonics Holdings
SENS
|
10.3 | $ 6.63 | 3.19 % | $ 277 M | ||
|
Castle Biosciences
CSTL
|
49.2 | $ 24.51 | 1.11 % | $ 681 M | ||
|
Thermo Fisher Scientific
TMO
|
70 | $ 476.83 | 2.2 % | $ 180 B | ||
|
Trinity Biotech plc
TRIB
|
87.2 | $ 0.6 | - | $ 61.9 M | ||
|
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | ||
|
Twist Bioscience Corporation
TWST
|
44.5 | $ 59.38 | 4.72 % | $ 3.55 B | ||
|
Charles River Laboratories International
CRL
|
65 | $ 164.3 | 0.28 % | $ 8.14 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
46.1 | $ 84.99 | 1.89 % | $ 10.7 B | ||
|
Personalis
PSNL
|
55.8 | $ 5.47 | 8.53 % | $ 324 M | ||
|
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
66.9 | $ 1.98 | -0.5 % | $ 8.76 M | ||
|
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
57.7 | $ 2.16 | 0.1 % | $ 4.96 M | ||
|
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 259.36 | 0.78 % | $ 21.6 B | ||
|
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
66.6 | $ 9.32 | 3.44 % | $ 2.02 B | ||
|
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | ||
|
Myriad Genetics
MYGN
|
52.3 | $ 4.74 | 1.18 % | $ 439 M | ||
|
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | ||
|
Natera
NTRA
|
81.5 | $ 204.38 | 4.94 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
44.9 | $ 194.63 | 2.8 % | $ 21.6 B | ||
|
Organovo Holdings
ONVO
|
79.8 | - | -2.3 % | $ 19.4 M |